HCA · Hca Healthcare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.11B | - | $19.16B | $18.61B | $18.32B | - | $17.49B | $17.49B | $17.34B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $133.00M | - | $139.00M | $130.00M | $126.00M | - | $111.00M | $100.00M | $78.00M | - |
| Total Operating Expenses | $16.82B | - | $16.74B | $16.19B | $15.99B | - | $15.58B | $15.26B | $15.09B | - |
| D&A | $930.00M | - | $889.00M | $863.00M | $860.00M | - | $842.00M | $819.00M | $795.00M | - |
| Operating Income | $2.29B | - | $2.42B | $2.42B | $2.33B | - | $1.91B | $2.24B | $2.25B | - |
| Interest Expense | $584.00M | - | $561.00M | $568.00M | $547.00M | - | $515.00M | $506.00M | $512.00M | - |
| Income Tax | $430.00M | - | $515.00M | $524.00M | $502.00M | - | $424.00M | $550.00M | $445.00M | - |
| Net Income | $1.62B | - | $1.64B | $1.65B | $1.61B | - | $1.27B | $1.46B | $1.59B | - |
| EPS - Basic | $7.25 | - | $7.05 | $6.91 | $6.52 | - | $4.94 | $5.60 | $6.01 | - |
| EPS - Diluted | $7.15 | - | $6.96 | $6.83 | $6.45 | - | $4.88 | $5.53 | $5.93 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $940.00M | $1.04B | $997.00M | $939.00M | $1.06B | $1.93B | $2.89B | $831.00M | $1.28B | $935.00M |
| Accounts Receivable | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | $9.96B |
| Inventory | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | $2.02B |
| Accounts Payable | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | $4.23B |
| Current Assets | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | $14.93B |
| Total Assets | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B |
| Current Liabilities | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | $12.65B |
| Long-term Debt | $39.49B | $41.60B | $38.40B | $39.38B | $41.06B | $38.33B | $38.28B | $36.31B | $37.16B | $37.17B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($6.30B) | ($6.03B) | ($5.33B) | ($4.39B) | ($3.52B) | ($2.50B) | ($2.18B) | ($1.60B) | ($1.61B) | ($1.77B) |
| Retained Earnings | ($5.98B) | ($5.72B) | ($5.02B) | ($4.09B) | ($3.16B) | ($2.12B) | ($1.81B) | ($1.17B) | ($1.19B) | ($1.35B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.01B | - | - | - | $1.65B | - | - | - | $2.47B | - |
| Investing Cash Flow | ($1.28B) | - | - | - | ($1.03B) | - | - | - | ($903.00M) | - |
| Financing Cash Flow | ($830.00M) | - | - | - | ($1.50B) | - | - | - | ($1.22B) | - |
| CapEx | $1.12B | - | - | - | $991.00M | - | - | - | $1.12B | - |
| Free Cash Flow | $895.00M | - | - | - | $660.00M | - | - | - | $1.35B | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 12.0% | - | 12.6% | 13.0% | 12.7% | - | 10.9% | 12.8% | 13.0% | - |
| EBITDA margin | 16.8% | - | 17.3% | 17.6% | 17.4% | - | 15.7% | 17.5% | 17.5% | - |
| Net margin | 8.5% | - | 8.6% | 8.9% | 8.8% | - | 7.3% | 8.4% | 9.2% | - |
| Free cash flow margin | 4.7% | - | - | - | 3.6% | - | - | - | 7.8% | - |
| FCF / Net income | 0.55 | - | - | - | 0.41 | - | - | - | 0.85 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 0.7% | - | 0.7% | 0.7% | 0.7% | - | 0.6% | 0.6% | 0.4% | - |
| Effective tax rate | 21.0% | - | 23.9% | 24.1% | 23.8% | - | 25.0% | 27.3% | 21.9% | - |
| Return on assets | 2.6% | - | 2.7% | 2.8% | 2.7% | - | 2.1% | 2.5% | 2.8% | - |
| Return on equity | -25.7% | - | -30.8% | -37.6% | -45.8% | - | -58.2% | -91.3% | -98.5% | - |
| Return on invested capital | 5.4% | - | 5.6% | 5.2% | 4.7% | - | 4.0% | 4.7% | 4.9% | - |
| Liquidity | ||||||||||
| Current ratio | 0.83 | 0.97 | 0.85 | 0.98 | 1.19 | 1.08 | 1.12 | 1.06 | 1.16 | 1.18 |
| Quick ratio | 0.75 | 0.86 | 0.76 | 0.86 | 1.06 | 0.97 | 1.00 | 0.94 | 1.02 | 1.02 |
| Cash ratio | 0.05 | 0.06 | 0.06 | 0.06 | 0.08 | 0.13 | 0.19 | 0.06 | 0.10 | 0.07 |
| Leverage | ||||||||||
| Debt / Equity | -6.27 | -6.90 | -7.20 | -8.96 | -11.67 | -15.34 | -17.54 | -22.69 | -23.01 | -20.95 |
| Debt / Assets | 0.64 | 0.69 | 0.64 | 0.66 | 0.69 | 0.64 | 0.64 | 0.63 | 0.65 | 0.66 |
| Debt / EBITDA | 12.28 | - | 11.61 | 12.01 | 12.88 | - | 13.93 | 11.88 | 12.22 | - |
| Interest coverage | 3.9x | - | 4.3x | 4.3x | 4.3x | - | 3.7x | 4.4x | 4.4x | - |
| Equity multiplier | -9.75 | -10.07 | -11.20 | -13.55 | -16.99 | -23.81 | -27.25 | -35.86 | -35.27 | -31.69 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.31 | - | 0.32 | 0.31 | 0.31 | - | 0.29 | 0.30 | 0.30 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 216d | - | 199d | 205d | 221d | - | 207d | 214d | 211d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 66.2x | - | 61.2x | 56.1x | 53.6x | - | 83.3x | 58.1x | 56.2x | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 5.6x | - | 5.3x | 5.0x | 4.7x | - | 6.0x | 4.9x | 5.2x | - |
| EV / EBITDA | 45.3x | - | 41.7x | 40.0x | 39.6x | - | 51.3x | 39.4x | 41.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.3% | - | 9.6% | 6.4% | 5.7% | - | 7.9% | 10.3% | 11.2% | - |
| Revenue CAGR (3y) | 7.0% | - | 8.6% | 7.9% | 7.0% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1.7% | - | 26.9% | 8.0% | 3.6% | - | 16.9% | 23.7% | 16.9% | - |
| Net income growth (YoY) | 0.6% | - | 29.4% | 13.1% | 1.2% | - | 17.7% | 22.5% | 16.7% | - |
| EPS growth (YoY) | 10.9% | - | 42.6% | 23.5% | 8.8% | - | 24.8% | 28.9% | 22.3% | - |
| EPS CAGR (3y) | 13.8% | - | 21.2% | 20.5% | 15.9% | - | -11.3% | 8.2% | 12.7% | - |
| EPS CAGR (5y) | 11.5% | - | 29.0% | 16.7% | 30.7% | - | 22.6% | 19.7% | 14.8% | - |
| FCF growth (YoY) | 35.6% | - | - | - | -51.1% | - | - | - | 122.9% | - |
| FCF CAGR (5y) | -7.7% | - | - | - | 4.8% | - | - | - | 21.9% | - |
| Book value growth (YoY) | -79.1% | -141.2% | -144.5% | -174.6% | -117.9% | -40.9% | 11.9% | 30.5% | 35.3% | 35.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$75.60B totalAmerican Group$26.45B · 35.0%
Atlantic Group$24.71B · 32.7%
National Group$21.28B · 28.1%
Corporate And Other$3.17B · 4.2%
Product / service
$2.46B totalProduct And Service Other$2.46B · 100.0%
Peer comparison
Same SIC group: Services-General Medical & Surgical Hospitals, NEC
Comparing HCA Healthcare against the 5 most active filers in the same SIC group.
Dividends
$2.94/share trailing 12 months · +8.9% YoY
| Ex-date | Per share |
|---|---|
| Mar 17, 2026 | $0.7800 |
| Dec 15, 2025 | $0.7200 |
| Sep 16, 2025 | $0.7200 |
| Jun 16, 2025 | $0.7200 |
| Mar 17, 2025 | $0.7200 |
| Dec 13, 2024 | $0.6600 |
| Sep 16, 2024 | $0.6600 |
| Jun 14, 2024 | $0.6600 |
| Mar 14, 2024 | $0.6600 |
| Dec 13, 2023 | $0.6000 |
| Sep 14, 2023 | $0.6000 |
| Jun 15, 2023 | $0.6000 |
| Mar 16, 2023 | $0.6000 |
| Dec 13, 2022 | $0.5600 |
| Sep 15, 2022 | $0.5600 |
| Jun 15, 2022 | $0.5600 |
| Mar 16, 2022 | $0.5600 |
| Dec 13, 2021 | $0.4800 |
| Sep 15, 2021 | $0.4800 |
| Jun 15, 2021 | $0.4800 |
| Mar 16, 2021 | $0.4800 |
| Dec 24, 2020 | $0.2680 |
| Oct 29, 2020 | $0.0720 |
| Feb 28, 2020 | $0.4300 |